Critical appraisal of tocilizumab in the treatment of moderate to severe rheumatoid arthritis
Author:
Open Access
- 1 March 2010
- journal article
- Published by Taylor & Francis in Therapeutics and Clinical Risk Management
- Vol. 6, 143-152
Abstract
Critical appraisal of tocilizumab in the treatment of moderate to severe rheumatoid arthritis Linda L Hushaw, Ray Sawaqed, Ghaleb Sweis, Jori Reigle, Anjali Gopal, Daniel Brandt, Nadia Sweis, James Curran, Timothy B Niewold, Nadera J SweissUniversity of Chicago, Section of Rheumatology, Chicago, ILL, USA Recent advances in our understanding of the role of interleukin (IL)-6 in autoimmunity and in particular rheumatoid arthritis (RA) have brought about important changes in the way we think about autoimmune diseases. Encouraging data from several phase III clinical trials of tocilizumab, a humanized monoclonal antibody against IL-6R, have led to its approval in Europe for the treatment of moderate to severe RA. Data on clinical efficacy, patient-reported outcomes, safety, and cost-effectiveness with the use of tocilizumab in patients with RA will be summarized in this review, with particular emphasis on phase III clinical trials. Furthermore, adverse events associated with the use of tocilizumab will be reviewed. Future clinical trials will evaluate the role of tocilizumab in other autoimmune diseases. The goal of this review is to describe the current understanding of the role of IL-6 in mediating the inflammatory response in RA, as well as the role of tocilizumab in the treatment of RA and the evolving role of this agent in other autoimmune diseases.Keywords: tocilizumab, rheumatoid arthritis, IL-6, methotrexateKeywords
This publication has 41 references indexed in Scilit:
- Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockadeAnnals of the Rheumatic Diseases, 2009
- Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapyModern Rheumatology, 2008
- Interleukin‐6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease‐modifying antirheumatic drugs: The tocilizumab in combination with traditional disease‐modifying antirheumatic drug therapy studyArthritis & Rheumatism, 2008
- Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trialThe Lancet, 2008
- The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double‐blind, placebo‐controlled, dose‐ranging trialArthritis & Rheumatism, 2006
- Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine familyInternational Immunopharmacology, 2005
- Prognostic value of inflammatory markers alone and in combination with blood lipids in patients with stable coronary artery diseaseEuropean Journal of Internal Medicine, 2005
- Efficacy, Tolerability and Cost Effectiveness of Disease-Modifying Antirheumatic Drugs and Biologic Agents in Rheumatoid ArthritisDrugs, 2005
- Clinical Usefulness of Very High and Very Low Levels of C-Reactive Protein Across the Full Range of Framingham Risk ScoresCirculation, 2004
- Disease-Modifying Antirheumatic DrugsDrugs, 1998